Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug PA5 targets arginine to starve advanced cancers

NCT ID NCT07702162

Recruiting now Disease control Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This phase 1 trial tests an experimental drug called PA5 in adults with advanced solid tumors that have not responded to standard treatments. PA5 is designed to break down arginine, an amino acid some cancers need to grow. The study aims to find the safest dose and check for side effects, with participants receiving the drug by intravenous infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PA5, a pegylated arginine deiminase dimer, given by intravenous infusion
What this could lead to
If successful, this could establish a safe dose for further testing of PA5 as a potential treatment for advanced solid tumors.
What could go wrong
This is an early phase 1 trial with only 49 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, 200072, China

    Contact

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350014, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.